Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γ Agonist against MPTP

Figure 3

LSN862 (LSN) induced protection of striatal catecholamines against MPTP dopaminergic loss. HPLC analysis of striatal catecholamine levels was performed in mice tissues obtained 21 days after treatment with MPTP or PBS and LSN or vehicle (mean ± SEM). (mean ± SEM; 𝑛=4--7 per group). ANOVA (Fisher’s LSD post hoc). (a) Dopamine: ^#𝑃<0.05 (vehicle + PBS versus vehicle + MPTP), *𝑃<0.05 (vehicle + MPTP versus 30 mg/kg LSN + MPTP). (b) DOPAC: ^#𝑃<0.05 (vehicle + PBS versus vehicle + MPTP). (c) HVA: ^#𝑃<0.05 (vehicle + PBS versus vehicle + MPTP). (d) DOPAC/HVA ratio.

(a)

(b)

(c)

(d)